Abstract:fi2AR is an important drug target protein involving many diseases. Biased drugs induce specific signaling and provide additional clinical utility to optimize fi2AR-based therapies. However, the biased signaling mechanism has not been elucidated. Motivated by the issue, we chose four agonists with divergent bias (balanced agonist, G-protein-biased agonist, and fi-arrestin-biased agonists) and utilized Gaussian accelerated molecular dynamics simulation coupled with a dynamic network to probe the molecular mechanisms of distinct biased activation induced by the structural differences between the four agonists. Our simulations reveal that the G-protein-biased agonist induces an open conformation with the outward shifts of TM6 and TM7 for the intracellular domain, which will be beneficial to couple G protein. In contrast, the fi- arrestin-biased agonists regulate an occluded conformation with a slightly outward movement of TM6 and an inward shift of TM7, which should favor fi-arrestin signaling. The balanced agonist does not induce an observable outward shift for TM6 but, along with a slight tilt for TM7, leads to an inactive-like conformation. In addition, our results reveal the first time that ICL3 presents specific conformations with different agonists. The G-protein-biased agonist drives ICL3 to open so that the G protein-binding pocket can be available, while the fi-arrestin-biased agonists induce ICL3 to form a closed conformation with a stable local a-helix. MM/PBSA analysis further reveals that the hydroxyl groups in the resorcinol of the G-protein-biased agonist form strong interactions with Y5.38 and S5.42, thus preventing tilting of the TM5 extracellular end. The catechol of the balanced agonist and the fi-arrestin-biased ones induces the rearrangement of two hydrophobic residues F6.52 and W6.48. However, different from the balanced agonist, the ethyl substituent of fi-arrestin-biased agonists forms additional hydrophobic interactions with W6.48 and F6.51 after the rearrangement, which should contribute to the fi-arrestin bias. The shortest pathway analysis further reveals that the three residues Y7.43, N7.45, and N7.49 are crucial for allosterically regulating G-protein-biased signaling, while the two residues W6.48 and F6.44 make an important contribution to regulate fi-arrestin-biased signaling. For the balanced agonist NE, the allosteric regulation pathway simultaneously involves the residue associated with G-protein-biased signaling like S5.46 and the residues related to fi-arrestin-biased signaling like W6.48 and F6.44, thus producing unbiased signaling. The observations could advance our understanding of the biased activation mechanism on class A GPCRs and provide a useful guideline for the design of biased drugs.

A New Series of Gs‐ and Β‐arrestin‐biased Β2‐adrenoceptor Agonists

Discovery of Β-Arrestin-biased Β2-Adrenoceptor Agonists from 2-Amino-2-phenylethanol Derivatives

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Arrestin-biased AT1R Agonism Induces Acute Catecholamine Secretion Through TRPC3 Coupling

Negative Allosteric Modulation of Arrestin Recruitment to the Β2‐adrenergic Receptor

Molecular basis of β-arrestin coupling to formoterol-bound β1-adrenoceptor

Small Molecule Modulators of Beta-arrestins

Β-Arrestin2 Recruitment by Β-Adrenergic Receptor Agonists and Antagonists

Molecular Mechanisms of Diverse Activation Stimulated by Different Biased Agonists for the 2-Adrenergic Receptor

β-arrestin and β-adrenergic Receptor

Biased agonism of carvedilol in the beta1-adrenergic receptor is governed by conformational exclusion

Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics

Recent progress in the development of β2 adrenergic receptor agonists: a patent review (2015-2020)

Mechanism of Β 2 AR Regulation by an Intracellular Positive Allosteric Modulator

Different conformational responses of the β2-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline

Different conformational responses of the <sub>2</sub>-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline

An Allosteric Modulator Binds to a Conformational Hub in the Β2 Adrenergic Receptor.

Studies on the Interactions Between Β2adrenergic Receptor and Gs Protein by Molecular Dynamics Simulations

Structural Insights into M1 Muscarinic Acetylcholine Receptor Signaling Bias Between Gαq and Β-Arrestin Through BRET Assays and Molecular Docking.

A novel <sub>2</sub>-AR agonist, Higenamine, induces -arrestin-biased signaling

Molecular Mechanism of the β3AR Agonist Activity of a β‐Blocker